Theranautilus
Overview
Theranautilus is a pioneering deep-tech startup focused on developing nanorobotic solutions for healthcare, particularly targeting the oral health sector. Established in 2020 and incubated at the Indian Institute of Science (IISc), it was co-founded by Professor Ambarish Ghosh, Dr. Debayan Dasgupta, and Dr. Peddi Shanmukh Srinivas. The company is based in Bengaluru, India. Theranautilus has recently secured $1.2 million in seed funding led by pi Ventures, with participation from Golden Sparrow Ventures and notable angel investors.
Recent Developments
- November 2024: Theranautilus announced raising $1.2 million in a seed funding round led by pi Ventures. The funding aims to accelerate the clinical development of its innovative nanorobotic solutions, particularly focusing on dental hypersensitivity treatment. This round also saw participation from Golden Sparrow Ventures, and angel investors like Abhishek Goyal, Founder and CEO of Tracxn, and Lalit Keshre, CEO of Groww. The funds will be used to establish an ISO-certified manufacturing facility and advance their go-to-market strategies, alongside preparing for the world’s first human trials for a nanorobotic healthcare device scheduled for 2025.
- September 2023: Theranautilus completed a successful animal trial demonstrating remarkable efficacy in treating dental hypersensitivity. The outcome brought the company closer to initiating human trials.
- January 2023: Theranautilus expanded its team by hiring key personnel with expertise in biocompatible materials and nanotechnology to strengthen their research and development department.
- 2022: The company shifted its primary focus to targeting dental hypersensitivity using nanorobots due to the significant global impact, with over two billion individuals affected. This strategic pivot has positioned Theranautilus to potentially revolutionize the dental care market, valued at approximately $6 billion.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2020 |
| Headquarters | Bengaluru, India |
| Founders | Professor Ambarish Ghosh, Dr. Debayan Dasgupta, Dr. Peddi Shanmukh Srinivas |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Pi Ventures, Golden Sparrow Ventures, Abhishek Goyal, Lalit Keshre |
| Industry | Nanotechnology and Healthcare |
| Number of Employees | Not specified |
Early History
Theranautilus was conceptualized in 2019 when Dr. Peddi Shanmukh Srinivas, while pursuing his Masters in Endodontic Microsurgery, recognized the limitations of traditional dental tools in precision surgery. Discovering Professor Ghosh’s research in nanorobotics, he saw potential applications in solving oral health issues. Subsequently, Srinivas collaborated with Professor Ghosh and Dr. Debayan Dasgupta to establish Theranautilus in 2020. The startup was incubated at the prestigious Indian Institute of Science, aligning its innovation trajectory with cutting-edge research in nanotechnology.
Company Profile and Achievements
Theranautilus stands at the forefront of integrating nanorobotics into healthcare solutions. Its core technology involves precision-engineered nanorobots that navigate dental tissues to deliver therapeutic agents directly to the site of injury or sensitivity.
- 2020: Founded at IISc, leveraging sophisticated nanorobotic technology to target healthcare issues.
- 2021: Secured initial patents for its groundbreaking technology focusing on dental applications.
- 2022: Successfully completed preclinical testing on animal models for its dental hypersensitivity treatments.
- 2023: Shifted focus primarily towards combating dental hypersensitivity, positioning itself to capture a significant market segment.
- 2024: Announced its first human trials scheduled for 2025, highlighting its commitment to lead the healthcare market with advanced nanotechnology solutions.
Current Operations and Market Position
Currently, Theranautilus focuses on dental healthcare, addressing issues like hypersensitivity by using magnetically controlled nanorobots. These nanorobots, made of biocompatible materials, are designed for precision delivery of treatments. This approach promises long-term relief compared to conventional methods. Theranautilus is strategically positioned to disrupt the $6 billion dental sensitivity market by offering a minimally invasive, fast-acting solution. The company's innovative edge lies in its patented technology and ability to perform targeted therapeutic procedures, setting a new standard in dental treatments.
Conclusion
Theranautilus is set to redefine the dental care industry with its novel use of nanorobotics, addressing a prevalent issue affecting billions worldwide. Its innovative approach not only holds transformative potential in oral healthcare but also lays the groundwork for future applications across various medical fields, including cancer therapy. As the company prepares for its first human trials in 2025, its trajectory indicates a strong potential to becoming a leader in nanotechnology-driven healthcare solutions globally.